Disruption of Ptk6 significantly delayed and reduced ERBB2-induced mammary gland tumor formation and metastasis, providing strong rationale for therapeutically targeting PTK6 alone or in combination with other agents in ERBB2/HER2-positive breast cancers. The gene discussed is ERBB2; the disease is breast cancer.